Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B-Cell Precursor Acute Lymphoblastic Leukemia research hub

A Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of Administration of Subcutaneous (SC) Blinatumomab in Pediatric Participants with Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B Cell Precursor Acute Lymphoblastic Leukemia (B-ALL)

This study is looking at a new way to give a medicine called blinatumomab (as an injection under the skin) to children and young people with a type of leukaemia. It aims to see how safe and effective it is for those whose leukaemia has come back or hasn't fully gone away.